Iridex Corporation announced a two-year clinical study demonstrating that MicroPulse transscleral laser therapy significantly reduces intraocular pressure (IOP) and medication use in patients with early to advanced glaucoma. The study, involving 84 eyes from 53 patients, showed IOP dropped from 22.32 mmHg to 14.05 mmHg, with an 86% success rate in open-angle glaucoma and 81% in angle-closure glaucoma. No complications or vision loss were reported, suggesting the therapy is a safe, effective option that could be used earlier in glaucoma treatment. This supports Iridex’s commitment to advancing laser treatments for eye diseases.
Iridex Corporation's clinical study on MicroPulse technology complements a health sector where 58 of 128 US stocks traded on Pluang rose today. For readers following the health sector, here is Pluang's market snapshot as of Oct 12, 2026 17:11 WIB: Humana Inc (HUM) rose 1.55% to USD 437.69 with a typical hold time of 51 days, Axogen Inc (AXGN) increased 1.47% to USD 36.66 with an 18-day hold, and Relay Therapeutics Inc (RLAY) fell 1.45% to USD 17.62 with a 2-day hold.
Harmony Biosciences announced that Peter Anastasiou will become President and CEO effective January 1, 2027, succeeding Jeffrey M. Dayno, who will retire at the end of 2026. Dayno will remain as a non-executive advisor through 2027 to support the com...
Zenas BioPharma presented new data on obexelimab at the 6th International Symposium on IgG4-Related Disease, highlighting sustained clinical activity in treating IgG4-RD. Phase 3 INDIGO open-label extension results showed a high probability of patien...
The St. Louis Blues and Gray Media announced a multi-year deal to broadcast 10 select Thursday games over-the-air on ABC 32 in St. Louis and 10 other markets during the 2026-27 NHL season. This expands access to Blues games for over 4.8 million house...
Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus n...
The European Commission has chosen Neo Performance Materials' Silmet 2.0 as one of 46 Strategic Projects under the EU's Critical Raw Materials Act, recognizing its importance in rare earth processing. Greenland Mines, a key shareholder in Neo, sees t...
